Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02283294 · ClinicalTrials.gov registry record · Phase 3
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
A Phase 3 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT02283294 is a Phase 3 study that has completed, run by University of South Florida. The registered enrollment target is 91 participants.
The verdict
NCT02283294, a Phase 3 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.
Interventions
- DRUG Apixaban
- DRUG Warfarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02283294
The ClinicalTrials.gov registry entry for NCT02283294 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT02283294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02283294 about?
NCT02283294 is a clinical study titled "Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation". The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.
What is the current status of trial NCT02283294?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2015-04. Estimated completion is 2019-06.
What interventions are being tested in trial NCT02283294?
The interventions under investigation include: Apixaban (DRUG), Warfarin (DRUG).
Who is sponsoring clinical trial NCT02283294?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.